# BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)

Study · id `cardio:ct-nct02398929` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02398929](<https://clinicaltrials.gov/study/NCT02398929>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02398929

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02398929. Allocation not applicable; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2021-01-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02398929, source copy `cardio:ctgov-nct02398929-2021-01-06`, retrieved 2026-10-26)
- Start date: 2013-01 (registry gives no type) (ClinicalTrials.gov record NCT02398929, source copy `cardio:ctgov-nct02398929-2021-01-06`, retrieved 2026-10-26)
- Primary completion: 2021-01-05 (actual) (ClinicalTrials.gov record NCT02398929, source copy `cardio:ctgov-nct02398929-2021-01-06`, retrieved 2026-10-26)
- Completion: 2021-01-05 (actual) (ClinicalTrials.gov record NCT02398929, source copy `cardio:ctgov-nct02398929-2021-01-06`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China (ClinicalTrials.gov record NCT02398929, source copy `cardio:ctgov-nct02398929-2021-01-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02398929-2021-01-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)
- Acronym: BRAVE
- Condition: Hypertension
- Intervention (Drug): Bisoprolol 2.5 mg
- Intervention (Drug): Placebo
- Lead sponsor: Chinese University of Hong Kong
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Bisoprolol (`cardio:bisoprolol`)
- Registry intervention is a member of this class by a sourced record link: Beta-blockers (drug class) (`cardio:beta-blockers`)
- Registry lists this organization as the lead sponsor: Chinese University of Hong Kong (`cardio:org-chinese-university-of-hong-kong`)

## Provenance

Content hash: de96f55f955bb4140c7103c1f56dca8e7d4c279e3f5cc150e15b4a2aa290f1b2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
